costs and treatment effects observed within the trial period and do not require extrapolation of effects beyond the trial period.However, modelling indicated that these longer term benefits are likely to double the mean difference in event-free time.Our results suggest that intensive management of patients with type 2 diabetes is a feasible and economically supportable option.We thank the patients and staff at the study centres for their cooperation and Andrew Briggs, Philip Bassett, Valeria Frighi, and Ziyah Mehta for their contributions.Contributors: AG helped plan and design the health economics study, supervised and participated in the analysis, coordinated the writing of the paper, and is the guarantor.MR compiled, maintained, and analysed the economic data and participated in interpreting the results and writing the paper.AMcG helped plan and design the health economics study and participated in supervising analysis, interpreting results, and writing the paper.PF helped plan and design the health economics study and participated in supervision and interpretation of results and revising the paper.RS developed the simulation model and participated in interpreting the results and writing the paper.CC was responsible for maintenance of the database, prepared trial data for analysis, discussed statistical aspects of the analysis, and participated in revising the paper.IS participated in data preparation, interpretation, and revision of the paper.AA helped to develop the simulation model and participated in interpreting the results and revising the paper.RH was a principal clinical investigator in the UK prospective diabetes study and participated in data preparation, analysis, and interpretation and revising the paper.
No takes yet. Share an insight, caveat, or question.
Martin Bobák (2000) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: